Purified anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_Pure_030206
C57BL/6 mouse splenocytes stained with purified CD4 (clone RM4-5) (filled histogram) or purified rat IgG2a, κ isotype control (open histogram).
  • RM4-5_Pure_030206
    C57BL/6 mouse splenocytes stained with purified CD4 (clone RM4-5) (filled histogram) or purified rat IgG2a, κ isotype control (open histogram).
  • RM4-5_Pure_CD4_Antibody_2_100219
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then the section was stained with 10 µg/ml of purified anti-mouse CD4 (clone RM4-5), and anti-mouse CD3ε (clone 500A2) Alexa Fluor® 594 (green) overnight at 4°C, followed by 2.5 µg/mL of Alexa Fluor® 647 anti-rat IgG (clone Poly4054) (red) for two hours at room temperature. Nuclei were counterstained with DAPI (blue). The image was captured by 10X objective.
Cat # Size Price Quantity Avail. Save
100505 50 µg 20,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100506 500 µg 56,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF®, IHC-F - Verified
IHC - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. For immunohistochemistry on frozen tissue sections, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Huppé CA, et al. 2018. Mucosal Immunol. 0.536111111. PubMed
  2. Oyarce K, et al. 2018. Front Immunol. 9:112. PubMed
  3. Godoy-Calderón MJ, et al. 2018. Oncotarget. 8:11370. PubMed
  4. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  5. Deng W et al. 2019. Cell reports. 27(6):1755-1768 . PubMed
  6. Kälin S et al. 2017. Cell metabolism. 26(3):475-492 . PubMed
  7. Van De Velde LA, et al. 2017. J Biol Chem. 292:15:00. PubMed
  8. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  9. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  10. Bignon A, et al. 2017. Front Immunol. 0.722222222. PubMed
  11. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  12. Goel S, et al. 2017. Nature. 548:471. PubMed
  13. Cui X, et al. 2017. J Immunol. 199:4066. PubMed
  14. Regan–Komito D, et al. 2017. Front Immunol. 1.459027778. PubMed
  15. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
  16. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  17. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  18. Manni M, et al. 2018. Nat Immunol. 1.074305556. PubMed
  19. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  20. Lee YJ, et al. 2018. FASEB J. 32:4658. PubMed
  21. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  22. Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed
  23. Atif SM, et al. 2019. JCI Insight. 4:e125494. PubMed
  24. Stebegg M, et al. 2019. Nat Commun. 2.113194444. PubMed
  25. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  26. Do DC, et al. 2019. JCI Insight. 4:e126832. PubMed
  27. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  28. Fritz Y, et al. 2017. J Invest Dermatol. 137:696. PubMed
  29. Williams SK, et al. 2018. Sci Rep. 8:13628. PubMed
  30. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  31. Abdel-Gadir A, et al. 2019. Nat Med. 25:1164. PubMed
  32. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  33. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  34. Heinrich A, et al. 2020. Cell Rep. 31:107513. PubMed
  35. Chihara N, et al. 2018. Nature. 558:454. PubMed
  36. King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed
  37. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  38. Umemoto T, et al. 2017. EMBO J. 36:2390. PubMed
  39. Yi J, et al. 2019. Mol Cells. 42:228. PubMed
  40. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  41. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  42. Hu J, et al. 2019. Am J Transl Res. 3.043055556. PubMed
  43. Vitiello GA, et al. 2018. Clin Cancer Res. 24:972. PubMed
  44. Shi B, et al. 2018. J Immunol. 200:586. PubMed
  45. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  46. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
  47. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  48. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  49. Guo Y, et al. 2008. Blood. 112:480. PubMed
  50. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  51. Schuhmann MK, et al. 2020. Circ Res. 127:1023. PubMed
  52. Costa B, et al. 2021. Cancers (Basel). 13:00. PubMed
  53. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  54. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  55. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
RRID
AB_312708 (BioLegend Cat. No. 100505)
AB_312709 (BioLegend Cat. No. 100506)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 10-02-2019

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account